Showing results (41-50 of 84) with videos related to

Sort By:
Pageof 9
Current Oncology (Toronto, Ont.)|May 26, 2026
High-Risk Cytogenetic Multiple Myeloma Remains a Therapeutic Challenge: A 15-Year Real-World AnalysisCarmel Awadallah, Anas Zayad, Shebli Atrash, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 20, 2022
Belantamab in Combination with Dexamethasone in Patients with Triple-class Relapsed/Refractory Multiple MyelomaTahani Atieh, Shebli Atrash, Nausheen Ahmed, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 14, 2020
Safety and Cost Benefits of the Rapid Daratumumab Infusion ProtocolIssam S Hamadeh, Emily S Reese, Justin R Arnall, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2021
Transition from Intravenous to Subcutaneous Daratumumab Formulation in Clinical PracticeIssam S Hamadeh, Donald C Moore, Allison Martin, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 28, 2022
Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple MyelomaDavid M Foureau, Barry A Paul, Fei Guo, et al.
Blood|June 8, 2012
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenanceSaad Z Usmani, Rachel Sexton, Antje Hoering, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 31, 2013
Patterns of central nervous system involvement in relapsed and refractory multiple myelomaAl-ola Abdallah, Shebli Atrash, Zainab Shahid, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 17, 2025
Efficacy and Safety of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Multicenter Real-World ExperienceAnas Zayad, Gray Magee, Razan Mansour, et al.
European Journal of Haematology|January 16, 2026
Comparative Efficacy of Daratumumab Based Regimens in Patients With Relapsed-Refractory Multiple Myeloma (RRMM) Aged 70 and Above: A Multicenter StudyRazan Mansour, Kimberly M Green, Chandler Graf, et al.
Current Oncology (Toronto, Ont.)|February 26, 2026
BCMA-Directed CAR T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma and Renal ImpairmentAlma Habib, Nausheen Ahmed, Abdullah Mohammad Khan, et al.
Pageof 9